Liv Veldeman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Liv Veldeman has a total of 381 co-authors. Here are the top co-authors by number of shared publications:
- Catharine Mary Louise West
The University of Manchester, Manchester, United Kingdom
31 shared publications - Elena Sperk
Mannheim Cancer Center, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
30 shared publications - Petra Seibold
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
30 shared publications - Ana Vega
Fundación Pública Galega de Medicina Xenómica (FPGMX), Servicio Galego de Saúde, Santiago de Compostela, Spain
29 shared publications - Christopher J. Talbot
University of Leicester, Leicester, UK
29 shared publications - Tiziana Rancati
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
29 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
STROBE diagram showing the selection of patient cohorts for the analysis of late RB and UI. RT, radiotherapy.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
STROBE diagram showing the selection of patient cohorts for the analysis of late RB and UI. RT, radiotherapy.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Appendix S1 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
List of REQUITE Consortium members. Author list on main manuscript refers to this as 'REQUITE Consortium'.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Appendix S1 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
List of REQUITE Consortium members. Author list on main manuscript refers to this as 'REQUITE Consortium'.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
Supplementary table 1: Cohort characteristics by treatment centre (site)
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
Supplementary table 1: Cohort characteristics by treatment centre (site)
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
A, Predicted probability (y-axis) of a patient developing late RB (top row) and late UI (second row) as derived from fixed-effects regression models for different treatment times (solar time of day, x-axis) and genotype for VAMP3 SNP rs11121022 and adjacent PER3 SNP rs172933, rs696305, rs35128310, rs488728, rs288640, and rs697689. Probabilities of developing each late side effect are given for patient groups grouped by genotype at each SNP. Possible patient genotypes are colored as follows: purple, homozygous for allele 1; green, heterozygous; yellow, homozygous for allele 2. Alleles are arbitrarily assigned as allele 1 or allele 2, and their assignments can be determined from B. Shaded areas show 95% CI for predictions. B, Proportion of patients in the study cohort (European population) with given genotypes for each SNP. Colors represent genotypes for homozygous alleles 1/1 (purple), heterozygotes (green), and homozygous allele 2 (yellow). Actual SNP alleles are provided in the text labels along with the expected proportion of patients with those genotypes according to population frequency estimates. C, Chromosome diagram showing the position of each SNP on chromosome 1 (GRCh38). The position of PER3 VNTR rs57875989 is shown in exon 18. Gene structures of VAMP3 and PER3 are shown beneath.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
A, Predicted probability (y-axis) of a patient developing late RB (top row) and late UI (second row) as derived from fixed-effects regression models for different treatment times (solar time of day, x-axis) and genotype for VAMP3 SNP rs11121022 and adjacent PER3 SNP rs172933, rs696305, rs35128310, rs488728, rs288640, and rs697689. Probabilities of developing each late side effect are given for patient groups grouped by genotype at each SNP. Possible patient genotypes are colored as follows: purple, homozygous for allele 1; green, heterozygous; yellow, homozygous for allele 2. Alleles are arbitrarily assigned as allele 1 or allele 2, and their assignments can be determined from B. Shaded areas show 95% CI for predictions. B, Proportion of patients in the study cohort (European population) with given genotypes for each SNP. Colors represent genotypes for homozygous alleles 1/1 (purple), heterozygotes (green), and homozygous allele 2 (yellow). Actual SNP alleles are provided in the text labels along with the expected proportion of patients with those genotypes according to population frequency estimates. C, Chromosome diagram showing the position of each SNP on chromosome 1 (GRCh38). The position of PER3 VNTR rs57875989 is shown in exon 18. Gene structures of VAMP3 and PER3 are shown beneath.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
Rectal bleeding and urinary incontinence base models
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
Rectal bleeding and urinary incontinence base models
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
Rectal bleeding sensitivity analyses
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
Rectal bleeding sensitivity analyses
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
Urinary incontinence sensitivity analyses
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
Urinary incontinence sensitivity analyses
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
Cohort characteristics and univariate analysis.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
Cohort characteristics and univariate analysis.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Table 3 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
Logistic regression for deterioration in RB from baseline to 2 years after radiotherapy.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
Logistic regression for deterioration in RB from baseline to 2 years after radiotherapy.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
Genes and SNP investigated for interaction with treatment time on radiotherapy side effects.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
Genes and SNP investigated for interaction with treatment time on radiotherapy side effects.